title: Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment.
abstract: Tumors exhibit immune escape properties that promote their survival. These properties include modulation of Ag presentation, secretion of immunosuppressive factors, resistance to apoptosis, and induction of immune deviation, e.g., shifting from Th1- to Th2-type responses. These escape mechanisms have proven to hamper several immunotherapeutic strategies, and efforts need to be taken to revert this situation. We have studied the immunological effects of introducing CD40 ligand (CD40L), a potent dendritic cell activation molecule, into the tumor micromilieu by adenoviral gene transfer. For this purpose, a murine bladder cancer model (MB49) was used in C57BL/6 mice. The MB49 cells are known to induce IL-10 in the tumor environment. IL-10 potently inhibits the maturation of dendritic cells and thereby also the activation of CTLs. In this paper we show that CD40L immunogene therapy suppresses IL-10 and TGF-beta production (2-fold decrease) and induces a typical Th1-type response in the tumor area (200-fold increase in IL-12 production). The antitumor responses obtained were MB49 cell specific, and the cytotoxicity of the stimulated CD8(+) cells could be blocked by IL-10. Adenovirus CD40L therapy was capable of regressing small tumors (five of six animals were tumor free) and inhibiting the progression of larger tumors even in the presence of other escape mechanisms, such as apoptosis resistance. Furthermore, CD40L-transduced MB49 cells promoted the maturation of dendritic cells (2-fold increase in IL-12) independently of IL-10. Our results argue for using adenovirus CD40L gene transfer, alone or in combination with other modalities, for the treatment of Th2-dominated tumors.
authors.affiliation: Clinical Immunology Division, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden. aloskog@bcm.tmc.edu
authors.forename: Angelica
authors.initials: A
authors.lastname: Loskog
authors.forename: Helena
authors.initials: H
authors.lastname: Dzojic
authors.forename: Sofia
authors.initials: S
authors.lastname: Vikman
authors.forename: Christina
authors.initials: C
authors.lastname: Ninalga
authors.forename: Magnus
authors.initials: M
authors.lastname: Essand
authors.forename: Olle
authors.initials: O
authors.lastname: Korsgren
authors.forename: Thomas H
authors.initials: TH
authors.lastname: Totterman
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D023201:CD40 Ligand / Q000235:genetics*; D003713:Dendritic Cells / Q000502:physiology; D005260:Female; D015316:Genetic Therapy; D016753:Interleukin-10 / Q000097:blood; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D001749:Urinary Bladder Neoplasms / Q000628:therapy
chemical_list: D016753:Interleukin-10; D023201:CD40 Ligand